openPR Logo
Press release

Inflammatory Bowel Disease (IBD) Clinical Market Expands as Biologics, JAK Inhibitors & Precision Gastroenterology Drive Next-Generation Care

11-28-2025 07:12 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Exactitude Consultancy

Inflammatory Bowel Disease (IBD) Clinical Market

Inflammatory Bowel Disease (IBD) Clinical Market

Inflammatory Bowel Disease (IBD)-including ulcerative colitis (UC) and Crohn's disease (CD)-is a chronic, immune-mediated gastrointestinal condition affecting millions worldwide. As biologics, small-molecule inhibitors, and personalized gastroenterology approaches advance, the IBD clinical market is undergoing a major transformation. This press release explores market growth factors, therapeutic innovations, key segments, and the evolving clinical strategies improving patient outcomes across the globe.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73633

Market Overview
The Global Inflammatory Bowel Disease Clinical Market is projected to grow at a strong CAGR of 7.2% from 2023 to 2030, driven by:
• Rising incidence of ulcerative colitis and Crohn's disease
• Strong adoption of biologics (anti-TNF, anti-IL-23, anti-integrin)
• Expansion of JAK inhibitors & S1P receptor modulators
• Advances in diagnostic imaging, endoscopy, and biomarker-based monitoring
• Greater awareness and early detection initiatives
IBD represents a long-term therapeutic challenge, requiring ongoing medication, monitoring, dietary management, and sometimes surgical intervention.

Key Takeaways
• Biologics and targeted small molecules are reshaping IBD treatment algorithms.
• Non-invasive diagnostics-stool biomarkers, capsule endoscopy, and AI-assisted imaging-are increasing early diagnosis accuracy.
• Personalized therapy, including therapeutic drug monitoring (TDM), is improving remission rates.
• Rising prevalence in Asia and emerging economies is expanding global clinical demand.

Market Story - Why IBD Clinical Management Is Evolving Rapidly
IBD is a chronic relapsing-remitting disease with no complete cure, requiring lifelong management. Its rising incidence is linked to:
• Diet & lifestyle changes
• Genetic predisposition
• Urbanization
• Increased immune dysregulation
• Gut microbiome alterations
Modern IBD care emphasizes:
• Early aggressive therapy for high-risk patients
• Biologics with improved response durability
• Oral small molecules (JAK, S1P modulators) offering convenience
• Advanced imaging & endoscopy for disease monitoring
• Personalized treatment strategies guided by biomarkers
The shift toward precision gastroenterology is delivering better remission rates, fewer hospitalizations, and improved quality of life.

Market Segmentation
By Disease Type
• Ulcerative Colitis (UC)
• Crohn's Disease (CD)

By Diagnosis Method
• Colonoscopy
• Endoscopy (Flexible Sigmoidoscopy)
• CT & MRI Enterography
• Capsule Endoscopy
• Stool Biomarkers (Calprotectin, Lactoferrin)
• Blood Tests & Genetic Markers

By Treatment Type
Conventional Therapies
• Aminosalicylates (5-ASA)
• Corticosteroids
• Immunomodulators (Azathioprine, 6-MP)
Biologics
• Anti-TNF Agents
• Anti-Integrin Therapies
• Anti-IL-12/23 and Anti-IL-23 Inhibitors
Targeted Small Molecules
• JAK Inhibitors
• S1P Receptor Modulators
Other Therapies
• Antibiotics
• Nutritional & Microbiome Therapies
• Surgical Interventions

By End User
• Hospitals
• Gastroenterology Clinics
• Diagnostic Centers
• Research Institutes
• Specialty IBD Centers
• Telemedicine Platforms & Home-Care Settings

By Region
• North America - Strong biologics adoption and specialized IBD centers
• Europe - High awareness and access to advanced therapies
• Asia Pacific - Fastest-growing due to increasing incidence and healthcare modernization
• Latin America - Rising diagnostics and access to biologics
• Middle East & Africa - Improving gastroenterology infrastructure

Explore Full Report here: https://exactitudeconsultancy.com/reports/73633/inflammatory-bowel-disease-clinical-market

Recent Developments
• Launch of next-generation IL-23 inhibitor biologics with superior remission rates.
• Development of JAK inhibitors and S1P modulators offering oral alternatives to biologics.
• AI-driven endoscopy systems for improved mucosal healing assessment.
• Research into microbiome-based therapeutics and fecal microbiota transplantation (FMT).
• Digital gastrointestinal monitoring tools enabling remote patient tracking.

Expert Quote - Irfan Tamboli (Required)
"IBD care is being transformed by precision medicine, advanced biologics, and digital diagnostic technologies. With rising global incidence, the need for personalized and long-term management approaches has never been more critical."
- Irfan Tamboli, Business Development Executive, Exactitude Consultancy

Key Market Drivers
• Increasing global prevalence of UC & Crohn's disease
• High adoption of biologics and targeted therapies
• Advances in endoscopic imaging and remote monitoring
• Strong R&D investment in immune-modulating drugs
• Expanding diagnostic access in emerging economies

Market Forecast & Outlook
Through 2030, the IBD clinical market will experience significant growth as:
• Biologics pipelines expand with IL-23-only therapies
• Oral small molecules become mainstream maintenance therapies
• Digital GI tools improve patient monitoring
• Personalized therapy and TDM become routine practice
Asia Pacific is expected to be the fastest-growing region, driven by urbanization, lifestyle shifts, and improved healthcare access.

Government & Regulatory Support
• Approval of new biologics and targeted therapies
• National programs raising awareness of gut health
• Health insurance policies supporting biologic reimbursement
• Research grants for gastrointestinal disease innovation

Conclusion
The inflammatory bowel disease clinical market is undergoing a major evolution fueled by biologic innovation, targeted therapies, and digital diagnostic advancements. As global prevalence rises, the market is poised for strong, sustained growth driven by precision treatment strategies and improved access to modern gastroenterology care.

This report is also available in the following languages : Japanese (炎症性腸疾患の臨床市場), Korean (염증성 장 질환 임상 시장), Chinese (炎症性肠病临床市场), French (Marché clinique des maladies inflammatoires de l'intestin), German (Klinischer Markt für entzündliche Darmerkrankungen), and Italian (Mercato clinico delle malattie infiammatorie intestinali), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73633

Related Reports

Multiomics Market
https://exactitudeconsultancy.com/reports/73501/multiomics-market

Single-Cell Omics Market
https://exactitudeconsultancy.com/reports/73503/single-cell-omics-market

Sustainable Laboratory Plasticware Market
https://exactitudeconsultancy.com/reports/73505/sustainable-laboratory-plasticware-market

Medical Waste Management Market
https://exactitudeconsultancy.com/reports/73507/medical-waste-management-market

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Inflammatory Bowel Disease (IBD) Clinical Market Expands as Biologics, JAK Inhibitors & Precision Gastroenterology Drive Next-Generation Care here

News-ID: 4293500 • Views:

More Releases from Exactitude Consultancy

Non Dispersive Infrared (NDIR) Sensor Market Forecast to Grow from ~USD 1.2 Billion in 2024 to ~USD 2.5 Billion by 2034
Non Dispersive Infrared (NDIR) Sensor Market Forecast to Grow from ~USD 1.2 Bill …
Pune, India - December 2025 - The global Non Dispersive Infrared (NDIR) Sensor Market is projected to grow significantly over the next decade, with market value expected to rise from approximately USD 1.2 billion in 2024 to about USD 2.5 billion by 2034, registering a compound annual growth rate (CAGR) of roughly 7.5% during the forecast period, according to a recent market research report by Exactitude Consultancy. Download Full PDF
Hyaluronic Acid Filler and Botulinum A Market Expected to Nearly Double by 2034
Hyaluronic Acid Filler and Botulinum A Market Expected to Nearly Double by 2034
Pune, India - December 2025: The global hyaluronic acid filler and botulinum A market is witnessing robust growth as aesthetic and medical injectable treatments gain widespread acceptance across age groups and geographies. The market, valued at approximately USD 6.4 billion in 2024, is projected to reach around USD 12.3 billion by 2034, registering a healthy compound annual growth rate (CAGR) of about 6-7% during the forecast period. Hyaluronic acid fillers and botulinum
Long Fiber Reinforced Thermoplastic Material Market Forecast to Surpass USD 26 Billion by 2034
Long Fiber Reinforced Thermoplastic Material Market Forecast to Surpass USD 26 B …
Pune, India - December 2025: The global long fiber reinforced thermoplastic (LFRT) material market is poised for strong growth over the next decade as industries seek robust, lightweight, and sustainable materials for high-performance applications. Valued at approximately USD 12.5 billion in 2024, the market is expected to reach around USD 26 billion by 2034, reflecting a healthy compound annual growth rate (CAGR) supported by expanding use in automotive, industrial, electrical &
Driver Monitoring System (DMS) Market Forecast to Grow from ~USD 1.2 Billion in 2024 to ~USD 3.5 Billion by 2034
Driver Monitoring System (DMS) Market Forecast to Grow from ~USD 1.2 Billion in …
Pune, India - December 2025 - The global Driver Monitoring System (DMS) Market is projected to experience robust growth over the next decade, with total market value expected to increase from approximately USD 1.2 billion in 2024 to around USD 3.5 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 11.5% during the forecast period. This surge is driven by increasing demand for enhanced vehicle safety features,

All 5 Releases


More Releases for IBD

Ace Therapeutics Unveils Imaging Services for Precise Characterization of IBD An …
Ace Therapeutics launched its translational imaging services specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models. New York, USA - May 28, 2025 - Ace Therapeutics, a leader in preclinical research solutions, launched its translational imaging solutions specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models. This breakthrough offering empowers researchers with high-resolution, quantitative data to enhance drug development and mechanistic studies. Image: https://www.getnews.info/uploads/3c0755ac659fa5075e809ffd1b893496.jpg Imaging techniques play a crucial
Inflammatory Bowel Disease (IBD) Market Size, Growth Insights, and Future Trends
Inflammatory Bowel Disease (IBD) continues to pose significant challenges for individuals and healthcare systems worldwide. With its increasing prevalence, the demand for effective treatments is driving market growth. The IBD treatment market is projected to grow from USD 19.91 billion in 2023 to USD 33.19 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period. Download Statistical Data: https://www.towardshealthcare.com/download-statistics/5149 Key Market Highlights • Crohn's Disease Dominates: Crohn's disease
Canada Inflammatory Bowel Disease (IBD) Market Size & Growth Analysis Report, 20 …
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease,
Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Visiongain has published a new report on Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios. Global Inflammatory Bowel Disease (IBD) drugs market was valued at US$ US$xx
US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 20 …
The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per
Global Inflammatory Bowel Disease (IBD) Therapeutics Market, Share, Trends & For …
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and